A recent report published by Infinium Global Research on the allergy vaccine market provides an in-depth analysis of segments and sub-segments in the global as well as regional allergy vaccine industry
Pune, India -- (SBWIRE) -- 11/27/2019 -- Infinium Global Research has added a new report on "Allergy Vaccine Market (Allergy Type - Allergic Asthma, Peanut Hypersensitivity, Seasonal Allergic Rhinitis, Grass Pollen Hypersensitivity, Tree Pollen Hypersensitivity, Cat Dander Allergy, and Other Allergy Type; Vaccine Type - Cat Allergy Vaccine, Peanut Allergy Vaccine, House Dust Mite Allergy Vaccine, Injectable MPL Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, and Other Vaccine Type): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025". Allergy can occur due to food inject into the body or due to inhalation into the lungs. Common types of allergies include allergic asthma, drug allergy, food allergy, allergic rhinitis, etc. Allergic reactions can range from mild to severe. In some severe cases, allergies can trigger a life-threatening reaction known as anaphylaxis. According to the IGR research analysts, the allergy vaccine market is anticipated to expand at a CAGR of 4.2% from 2019 to 2025.
Ask for Sample Copy of Research Report with Table of Content @ https://www.infiniumglobalresearch.com/reports/sample-request/15273
Growing Research and Development Activities for the Development of Allergy Vaccines
The key factors driving the growth of the market are the growing prevalence of allergic diseases and new research activities for the development of allergy vaccines by private and government industries. Considering the stats published by AAFA, more than 50 million Americans have experienced various types of allergies each year and so it has become the 6th leading cause of chronic illness in the United States.
Moreover, a recent study published by World Allergy Organization (WAO), Allergies and related diseases including asthma, rhinosinusitis, atopic dermatitis and life-threatening food, drug, and stinging insect allergies affect at least 30% of the population and nearly 80% of families. However, high costs associated with the vaccines and the presence of limited manufacturers can restrain the growth of the market. Despite the headwinds, the market is expected to generate substantial demand opportunities during the forecast period due to the rising awareness about allergy diseases and treatment among the people globally.
The Allergic Asthma Segment Leads the Allergy Vaccine Market in 2019
The allergy vaccine market can be segmented by allergy type and vaccine type. Based on allergy type the market can be further classified into allergic asthma, peanut hypersensitivity, seasonal allergic rhinitis, grass pollen hypersensitivity, tree pollen hypersensitivity, cat dander allergy, and other allergy types. Among these, seasonal allergic rhinitides dominate the market owing to its increasing prevalence worldwide.
Allergic rhinitis affects between 10% and 30 % of the population. Furthermore, based on the vaccine type the market can be divided into cat allergy vaccine, peanut allergy vaccine, house dust mite allergy vaccine, injectable MPL allergy vaccine, ragweed allergy immunotherapy vaccine and others. A Switzerland-based company revealed it's developing a new vaccine for cat allergies that are administered directly to the animal instead of a person. Though, not yet available, the vaccine targets Fel d 1, a common feline allergen that collects in the animal's fur.
Enquire here Get Customization & Check Discount for Report @ https://www.infiniumglobalresearch.com/reports/request-discount/15273
North America Expected to Dominate the Market in the Forecast Period
Based on geography the allergy market is segmented into North America, Europe, Asia-Pacific, and RoW. North America is expected to dominate the market in the forecast period, followed by Europe. Growing cases of allergy diseases in these regions contributing to the high market share. The Asia Pacific is the emerging market for the allergy vaccine market. Based on the stats provided by the Asia Pacific Association of Allergy (APAAACI) in Asia-Pacific, the prevalence of allergic rhinitis is variously reported and ranging around 8–10% of the population (in Korea) to more than 50% (among adults in Vietnam and Thailand).
Allergy Vaccine Industry: Competitive Analysis
Key players operating in the market are Circassia, Cytos Biotechnology AG, DVB Technologies SA, Allertein Therapeutics, Stallergenes Greer plc, Merck & Co., Inc., Allergy Therapeutics, and Novartis International AG. Among these Allergy Therapeutics who are working on pollen allergy vaccines have two vaccines Pollinex® Quattro Grass and Pollinex® Quattro Ragweed in phase III stage and one vaccine Pollinex® Quattro Tree in phase II stage. On the other side, Merck has its vaccine allergic rhinitis and allergic asthma in phase II and phase III stage respectively.
Browse Detailed TOC and Description of "Allergy Vaccine Market"
Reasons to Buy this Report:
=> Comprehensive analysis of global as well as regional markets of the allergy vaccine.
=> Complete coverage of all the product type and application segments to analyze the trends, developments, and forecast of market size up to 2025.
=> Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.
=> Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.